
    
      Prospective, observational, unblinded, multi-site study designed to collect data on patients
      implanted with a Model 106 VNS Therapy System from baseline through an EMU stay of up to 5
      days. After the EMU stay, patients will continue follow-up for safety for approximately two
      years or until final regulatory approval of the product.
    
  